Isorhamnetin protects melanocytes against CD8+ T cell-mediated apoptosis and reduces inflammation in vitiligo-afflicted mouse
- PMID: 40812210
- DOI: 10.1016/j.biopha.2025.118456
Isorhamnetin protects melanocytes against CD8+ T cell-mediated apoptosis and reduces inflammation in vitiligo-afflicted mouse
Abstract
Background: Vernonia anthelmintica (L.) Willd., containing isorhamnetin (ISO) as an active compound, is a conventional treatment for vitiligo within the Xinjiang region. We previously demonstrated the protective role of ISO in mitigating oxidative damage within HaCaT cells, suggesting its therapeutic potential in treating vitiligo. However, its mechanism and effect on melanocytes immune damage remain unclear.
Aim: Here, we examined the effect of ISO on inflammation and apoptosis in melanocytes. Moreover, we comprehensively analyzed key genes in vitiligo treatment.
Methodology: We employed flow cytometry, RT-PCR, ELISA, and western blotting to detect apoptosis and the expression of inflammatory factors and apoptotic proteins. Hematoxylin-eosin staining assays were used to detect infiltration and inflammatory factors in the vitiligo mouse epidermis. We also used RNA sequencing to identify significantly dysregulated differentially expressed genes in vitiligo mice. Additionally, protein-protein interaction network analysis and validation of RNA-seq data were used to identify the core targets associated with vitiligo treatment. Finally, we investigated the mechanism by which ISO binds with four specific target proteins by performing molecular docking and core target and Notch signal function analyses.
Results and conclusion: CD8 + T cells significantly reduced melanocyte viability and increased apoptosis. However, ISO pretreatment improved cell viability and reduced apoptosis. ISO also downregulated proinflammatory cytokines (TNF-α, IFN-γ, IL-6, and IL-8) and chemokines (CXCL9 and CXCL10), as well as p53 and Bcl-2 expression at protein levels in vitiligo mouse models. RNA sequencing identified and molecular docking suggested key differentially expressed genes (PTK7, DLL1, IL21R, and CD226) as potential targets for treatment. KEGG analysis indicated that ISO plays a protective role through the Notch signaling pathway. Further functional experiments suggested that inhibition of PTK7/DLL1 and Notch signals reversed the apoptosis-protective effect of ISO on melanocytes, emphasizing its potential as a therapeutic option for vitiligo treatment.
Keywords: Apoptosis; CD8+ T cells; Isorhamnetin; Melanocyte; Vitiligo.
Copyright © 2025 The Authors. Published by Elsevier Masson SAS.. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Comprehensive single-cell chromatin and transcriptomic profiling of peripheral immune cells in nonsegmental vitiligo.Br J Dermatol. 2025 Jun 20;193(1):115-124. doi: 10.1093/bjd/ljaf041. Br J Dermatol. 2025. PMID: 39888372
-
Isorhamnetin protects against D-GalN/LPS-induced acute liver injury in mice through anti-oxidative stress, anti-inflammation, and anti-apoptosis.BMC Complement Med Ther. 2025 Aug 2;25(1):297. doi: 10.1186/s12906-025-04949-0. BMC Complement Med Ther. 2025. PMID: 40753249 Free PMC article.
-
Prescription of Controlled Substances: Benefits and Risks.2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 30726003 Free Books & Documents.
-
Systemic treatments for metastatic cutaneous melanoma.Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2. Cochrane Database Syst Rev. 2018. PMID: 29405038 Free PMC article.
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2020 Jan 9;1:CD011535. doi: 10.1002/14651858.CD011535.pub3. PMID: 29271481 Free PMC article. Updated.
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous